Validation and Characterization of Transcatheter Aortic Valve Effective Orifice Area Measured by Doppler Echocardiography  by Clavel, Marie-Annick et al.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 4 , N O . 1 0 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 1 . 0 6 . 0 2 1O R I G I N A L R E S E A R C H
Validation and Characterization of
Transcatheter Aortic Valve Effective Oriﬁce Area
Measured by Doppler Echocardiography
Marie-Annick Clavel, DVM, MSC, Josep Rodés-Cabau, MD, Éric Dumont, MD,
Rodrigo Bagur, MD, Sébastien Bergeron, MD, Robert De Larochellière, MD,
Daniel Doyle, MD, Éric Larose, MD, MSC, Jean G. Dumesnil, MD,
Philippe Pibarot, DVM, PHD
Québec, Québec, Canada
O B J E C T I V E S The objectives were to compare different Doppler echocardiographic methods for the
measurement of prosthetic valve effective oriﬁce area (EOA) following transcatheter aortic valve implantation
(TAVI) and to determine the factors inﬂuencing the EOA of transcatheter balloon expandable valves.
B A C KG ROUND Previous studies have used different methods for the measurement of the valve
EOA following TAVI. Factors inﬂuencing the EOA of transcatheter valves are unknown.
METHOD S A total of 122 patients underwent TAVI with the use of the Edwards-SAPIEN valve (Edwards
Lifesciences, Irvine, California). The EOA was measured by transthoracic echocardiography at hospital
discharge, 6 months and 1 year after TAVI with the use of 2methods as described in previous studies. In Method
#1 (EOA1), LVOT diameter (LVOTd) entered in the continuity equation was measured at the base of prosthesis
cusps whereas, in Method #2 (EOA2), LVOTd was measured immediately proximal to the prosthesis stent.
R E S U L T S The average EOA2 (1.57  0.41 cm
2) was larger (p  0.01) than the EOA1 (1.21  0.38 cm
2).
Accordingly, incidence of severe PPM (indexed EOA 0.65 cm2/m2) was 3-fold lower with the use of EOA2
than with EOA1 (9% vs. 33%; p  0.001). Mean transprosthetic gradient correlated better (p  0.03) with
indexed EOA2 (r  0.70, p  0.0001) than with indexed EOA1 (r  0.58, p  0.0001). Intraobserver and
interobserver variability were lower for EOA2 compared to EOA1 (intra: 5% vs. 7%, p 0.06; inter: 6% vs. 14%; p
0.001). Aortic annulus size was the sole independent determinant (p 0.01) of prosthetic valve EOA2. The average
EOA varied from 1.37  0.23 cm2 for aortic annulus size 19 mm up to 1.90  0.17 cm2 for size 23 mm.
CONC L U S I O N S When estimating the EOA of Edwards-SAPIEN valves by Doppler-echocardiography, it is
recommended to use the LVOT diameter and velocity measured immediately proximal to the stent. The main
determinant of the EOA of transcatheter valves is the patient’s annulus size and these valves provide excellent
hemodynamics even in patients with a small aortic annulus. (J Am Coll Cardiol Img 2011;4:1053–62) © 2011 by
the American College of Cardiology Foundation
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ranscatheter aortic valve implantation (TAVI)
has emerged as an alternative to standard
aortic valve replacement (AVR) in high-risk
patients with severe aortic stenosis. The
ortic valve effective orifice (EOA) is one of the
ain Doppler echocardiographic index utilized
o characterize the hemodynamic performance of
rosthetic valves and to identify the presence of
rosthesis–patient mismatch (1,2). Accurate esti-
See page 1063
mation of the EOA is also crucial for the post-
procedural follow-up of valve function and for the
detection of prosthesis stenosis. The design of
TAVI prosthetic valves is markedly different from
that of surgical prostheses. In particular, the stent of
TAVI valves is longer, and its proximal portion
extends deeper into the left ventricular
outflow tract (LVOT), whereas with sur-
gical prostheses, it is located at the level of
the aortic annulus (intra-annular implan-
tation) or at the level of the Valsalva
sinuses (supra-annular implantation). It
remains unknown whether these differ-
ences in valve design alter the accuracy of
the Doppler echocardiographic estimation
of the prosthetic valve EOA following
TAVI. Moreover, pre- or periprocedural
factors influencing the EOA of transcath-
eter valves remain unknown.
The calculation of the EOA with the
use of the continuity equation requires
the measurement of 3 variables: the
LVOT diameter and the LVOT and
transprosthetic flow velocities. In previ-
ous studies, 2 methods have been used to estimate
the EOA of TAVI prostheses: some investigators
have used the LVOT diameter measured at the
base of the prosthetic valve leaflets, whereas
others used the diameter measured just proximal
to the prosthesis stent (3– 6).
The first objective of this study was to compare the
accuracy and reliability of these 2 methods for the
measurement of EOA following TAVI. The sec-
ond objective was to identify the factors determin-
ing the EOA of transcatheter balloon-expandable
valves.
M E T H O D S
A total of 122 patients diagnosed with symptomatic
ent
t
arsevere aortic stenosis who underwent TAVI with tthe Edwards-SAPIEN valve (Edwards Life-
sciences, Irvine, California) at the Québec Heart &
Lung Institute were included in this study. TAVI
was approved under the compassionate clinical use
program approved by the Canadian Department of
Health and Welfare (Ottawa, Ontario, Canada) for
patients with symptomatic severe AS considered
either nonoperable or very high-risk surgical candi-
dates. All patients provided signed informed con-
sent for the procedures.
Based on transesophageal echocardiographic
(TEE) measurements of the aortic valve annulus,
the 23-mm valve was implanted if the annulus was
between 17 and 21 mm, and the 26-mm valve was
implanted if the aortic annulus measured between
22 and 25 mm. A total of 63 patients (52%)
received the 23-mm valve, and 59 patients (48%)
received the 26-mm valve. All clinical, echocardio-
graphic, procedural, and post-procedural data were
prospectively collected.
Doppler echocardiography. Patients underwent a
complete transthoracic echocardiography before
the procedure, and early (pre-discharge exam), 6
months, and 1 year after the procedure. The
transvalvular gradients were measured with the
use of the Bernoulli formula, and the post-
procedural EOA was determined by the continu-
ity equation using 2 methods. In Method #1
(EOA1), the LVOT diameter entered in the
ontinuity equation was measured at the base of
he prosthetic valve leaflets (LVOTd1); whereas in
ethod #2 (EOA2), the LVOT diameter was mea-
ured immediately proximal to the prosthesis stent
LVOTd2) (Figs. 1A and 1B):
EOA1 LVOTd12 2 VTILVOTVTIAo
EOA2 LVOTd22 2 VTILVOTVTIAo
where VTILVOT and VTIAO are the velocity time-
ntegrals of the LVOT and transprosthetic flow,
espectively. To avoid the region of subvalvular
cceleration, the pulsed-wave Doppler sample
olume was positioned at 0.5 to 1.0 cm below the
nsertion of the bioprosthetic valve leaflets, i.e.,
mmediately proximal to the prosthesis stent.
We measured the energy loss coefficient (ELC)A B B R E V I A T I O N S
A N D A C R O N YM S
AVR aortic valve replacem
ELC energy loss coefficien
OA aortic valve effective
orifice
LV left ventricle/ventricul
LVOT left ventricular
utflow tract
PM prosthesis–patient
ismatch
AVI transcatheter aortic
alve implantation
EE transesophageal
chocardiography/o take into account the pressure recovery phenom-
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1055enon that may occur downstream of the valve in
patients with small aortic diameters (7):
ELC1
EOA1AA
AAEOA1
ELC2
EOA2AA
AAEOA2
where AA is the aortic cross-sectional area (in
square centimeters) measured approximately 1 cm
Figure 1. Measurements of LVOT Diameter
(A) Shows the transthoracic echocardiography measurement of left
ventricular outﬂow tract (LVOT) diameter with the use of Methods
#1 and #2. (B) Is a schematic representation of these measure-
ments. The blue line is the LVOT diameter measured at the base of
the prosthetic valve leaﬂets (LVOTd1, Method #1), and the pink line
is the diameter measured immediately proximal to the ventricular
border of the stent (LVOTd2, Method #2).downstream of the sinotubular junction.We also calculated the Doppler velocity index:
DVI
VTILVOT
VTIAo
Twenty-six patients were randomly selected and
measurements of EOA were repeated in these
patients by 2 independent observers. The intraob-
server and interobserver measurement variability
was calculated. The prosthetic valve EOAs were
indexed for body surface area. Moderate and severe
prosthesis–patient mismatch (PPM) were defined
as an indexed EOA 0.85 and 0.65 cm2/m2,
respectively (1).
Subanalysis in patients with normal ﬂow rate. To
alidate the measurements of EOA obtained by
ethods #1 and #2, we examined the relationship
etween mean transprosthetic gradient and the
OA indexed for body surface area. However, it
as been shown that an important proportion of
atients with severe aortic stenosis have reduced
troke volume, and thus low transvalvular flow rate,
nd this situation may occur in patients with low
eft ventricular (LV) ejection fraction as well as in
hose with preserved LV ejection fraction (8–10).
n low flow–state conditions, the gradient may be
seudo-normalized and the EOA may be pseudo-
everized, which may alter the relationship between
OA and gradient (8–10). So, to validate the
ethods used for EOA measurement, we per-
ormed a subanalysis of the Doppler echocardio-
raphic data in the subset of patients with stroke
olume index 35 ml/m2 (9).
Statistical analysis. Results are expressed as mean 
SD or percentages unless otherwise specified.
Changes in Doppler echocardiographic variables dur-
ing post-procedural follow-up were analyzed with the
use of a 1-way analysis of variance for repeated
measures followed by a Tukey post hoc test. Correla-
tion and agreement between variables were deter-
mined with the use of the Pearson correlation and
Bland-Altman (11) methods, respectively. Correlation
coefficients were compared using the Wolfe test.
Intraobserver and interobserver variability between
methods of measurement were calculated by dividing
the absolute value of the difference between the 2
measurements by the average value of the measure-
ments, and analyzed with the use of the 2-sided paired
Student t test. Relationship between indexed EOA
and mean gradient was assessed with multiple non-
linear regression models, and the equation providing
the best fit was retained. Individual and multivariable
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variables associated with prosthetic valve EOA. Given
that multiple measurements per patient were included
in the correlation, regression, and Bland-Altman anal-
yses, the significance testes were adjusted with the use
of Dunn/Sidak correction. A p value 0.05 was
considered statistically significant. The statistical anal-
yses were performed with the JPM version 8.01 (SAS
Institute, Cary, North Carolina) and Table Curve
version 5.01 (curve-fitting analyses, Systat Software,
Chicago, Illinois) software programs.
R E S U L T S
Baseline characteristics of the 122 patients included
in the study are presented in Table 1. Mean
Table 1. Baseline Clinical and Procedural Characteristics
Age, yrs 80 8
Male 56 (46)
Body surface area, m2 1.71 0.22
Obesity 22 (18)
NYHA functional class III to V 114 (93)
Diabetes 35 (29)
Dyslipidemia 100 (82)
Hypertension 115 (94)
Chronic obstructive pulmonary disease 47 (39)
Coronary artery disease 90 (74)
Previous myocardial infarction 58 (48)
Society of Thoracic Surgeons score, % 9.0 6.3
Logistic EuroSCORE, % 24.0 15.6
Left ventricular ejection fraction, % 53 15
Values are mean  SD or n (%).
EuroSCORE  European System for Cardiac Operative Risk Evaluation;
NYHA  New York Heart Association.
Table 2. Baseline and Follow-Up Doppler Echocardiographic Da
Pre-Procedural
(n  122)
Early Post-Proced
(n  118)
Gradient, mm HG
Peak gradient 64 25 21 9
Mean gradient 39 16 11 5
LVOTd, mm
LVOTd1 20.3 1.9 19.4 1.7
LVOTd2 21.0 2.4 22.2 1.6
EOA, cm2
EOA1 0.62 0.20 1.21 0.43
EOA2 0.69 0.22 1.57 0.46
ELC, cm2
ELC1 0.67 0.23 1.61 0.55
ELC2 0.74 0.27 2.09 0.56
Doppler velocity
index
0.19 0.05 0.41 0.12ELC  energy loss coefﬁcient; EOA  effective oriﬁce area; LVOTd  left ventriculafollow-up time was 11  10 months. Thirty (25%)
atients died during follow-up. After TAVI, mild
nd moderate prosthetic valve regurgitation was
resent in 14% and 5% of patients, respectively. The
everity of regurgitation remained stable during
ollow-up.
Tables 2 and 3 show the Doppler echocardio-
raphic data at baseline and at the post-TAVI
ollow-up time points for the whole cohort and for the
ubset of patients who had a complete (up to 1 year)
oppler echocardiographic follow-up, respectively.
Comparison of the 2 methods for the estimation of
valve EOA. Figure 2 shows the Bland-Altman plot
comparing values of EOAs obtained by Method #1
versus Method #2. The average EOA obtained by
Method #2 was larger than the EOA obtained by
Method #1 (EOA2  1.57  0.41 cm
2 vs.
EOA1 1.21  0.38 cm
2; p 0.01). This difference
was due to the much smaller LVOT diameter measured
by Method #1 versus Method #2 (LVOTd2 
2.1 1.7 mm vs. LVOTd1  19.3 1.6 mm;
p 0.001). Accordingly, the incidence of severe PPM
was 3-fold lower with the use of EOA2 than EOA1:
% vs. 33%. The ELC was also significantly lower when
alculated with EOA1 versus EOA2 (ELC1 
1.50  0.64 cm2 vs. ELC2  2.03  0.77; p 
0.001). There was a borderline significant decrease
in EOA1 during follow-up (p  0.05), whereas
EOA2 remained stable (p  0.46) (Table 3). The
eak and mean gradients and the Doppler velocity
ndex also remained unchanged during follow-up.
nterobserver and intraobserver variability were
ower for LVOTd2 than LVOTd1 (intra: 3  3%
vs. 7  10%, p  0.02; inter: 4  3% vs. 8  9%;
the Whole Cohort
6-Month Post-Procedural
(n  63)
1-Year Post-Procedural
(n  47)
18 8 18 8
10 4 10 4
19.4 1.7 19.0 1.6
22.0 1.8 21.7 1.7
1.25 0.34 1.15 0.28
1.60 0.37 1.52 0.36
1.57 0.58 1.42 0.60
2.05 0.65 1.93 0.60
0.42 0.08 0.41 0.08ta in
uralr outﬂow tract diameter.
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1057p  0.001) and for EOA2 than for EOA1 (intra:
 5% vs. 7  14%, p  0.06; inter: 6  6% vs.
14  15%; p  0.001) (Fig. 3).
Relationship between EOA and gradients in patients
with normal ﬂow rate. In a subanalysis that included
only the data from patients with a stroke volume
index 35 ml/m2, mean transprosthetic gradient
orrelated better (p  0.03) with indexed EOA2
(r  0.70, p  0.0001) than with indexed EOA1
(r  0.58, p  0.0001) (Fig. 4).
Determinants of transcatheter valve EOA. WHOLE
OHORT. The variables that correlated with pros-
thetic valve EOA2 in the whole cohort were: male
gender (r  0.42; p  0.0001), body surface area
(r  0.31; p  0.006), baseline native valve EOA
(r 0.29; p 0.02), stroke volume index (r 0.30;
p  0.02), aortic annulus size measured by TEE
(r  0.45; p  0.0001), and prosthesis size (r 
0.43; p  0.0001). On multivariable annulus size
(r  0.37; p  0.004) and baseline stroke volume
index (r  0.25; p  0.04) remained independent
predictors of EOA2.
SUBSET OF PATIENTS WITH NORMAL FLOW
RATE. In patients with a stroke volume index 35
l/m2, the variables that correlated with prosthetic
alve EOA2 were: body surface area (r  0.34, p 
0.006), baseline native valve EOA (r  0.26, p 
0.03), stroke volume index (r 0.23, p 0.04), aortic
annulus size (r  0.46, p  0.0001), and prosthesis
size (r  0.38, p  0.0001). In multivariable analysis,
Table 3. Baseline and Follow-Up Echocardiographic Data for
Echocardiographic Follow-Up
Pre-Procedural
(n  47)
Early Post-Procedura
(n  47)
Gradient, mm Hg
Peak gradient 67 21 19 7
Mean gradient 41 14 10 4
LVOTd, mm
LVOTd1 20.1 1.6 19.5 1.3
LVOTd2 20.7 2.3 21.8 1.5
EOA, cm2
EOA1 0.62 0.14 1.28 0.38
EOA2 0.67 0.17 1.60 0.40
ELC, cm2
ELC1 0.71 0.16 1.55 0.51
ELC2 0.76 0.21 2.06 0.55
Doppler velocity index 0.20 0.05 0.43 0.12
The p value is for the analysis of variance for repeated measures that included on
data were excluded from this analysis.
Abbreviations as in Table 2.only aortic annulus size was associated with prostheticvalve EOA2 (r  0.43, p  0.01). Table 4 shows the
values of EOA2 for the different subclasses of annulus
ize in patients with normal flow rate.
Incidence of prosthesis–patient mismatch. The aver-
age aortic annulus size measured by TEE at the time
of TAVI was 21 2 mm, and 50% of patients had an
annulus size21 mm. The incidence of moderate and
evere PPM estimated with the use of indexed EOA2
was 20% and 9%, respectively, in the whole cohort and
18% and 6% in the subset of patients with normal
stroke volume index. The incidence of severe PPM in
the whole cohort was higher in patients with an
EO
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Figure 2. Agreement Between the 2 Methods for Estimation of Va
This graph shows the Bland-Altman plot comparing Method #1 and
ents (n  47) With Complete Doppler
6-Month Post-procedural
(n  47)
1-Year Post-Procedural
(n  47) p Value
18 6 19 8 0.78
10 3 10 4 0.46
19.4 1.7 19.0 1.6 0.04
21.7 1.7 21.7 1.7 0.32
1.26 0.37 1.14 0.28 0.05
1.56 0.39 1.53 0.36 0.46
1.54 0.55 1.40 0.39 0.12
2.04 0.61 1.95 0.57 0.44
0.42 0.08 0.41 0.08 0.57
e post-procedural data. The data of the native valve Doppler echocardiographic3.0
lve Area
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1058annulus size 21 mm (14%) compared with those
ith larger annulus (4%) (Fig. 5).
D I S C U S S I O N
The main findings of this study are:
1. When estimating the EOA of transcatheter
balloon expandable valves by the continuity
equation method, it is recommended to use the
LVOT diameter and velocity measured imme-
diately proximal to the stent.
. The EOA obtained by this method correlates
better with transprosthetic gradient and has
lower intraobserver and interobserver measure-
Measurements Average, cm2
EOA1: 7±14%
EOA2: 5 ± 5%
p = 0.06
1.0 1.5 2.0 2.5
Measurements Average, cm2
 14±15%
  6 ± 6%
p <0.001
1.0 1.5 2.0 2.5
f Prosthetic Valve EOA Measurements
Bland-Altman plots comparing the intraobserver (A) and interob-
r the measurements of the prosthetic valve effective oriﬁce area
lue dots) and EOA Method #2 (pink dots) in a subset of 26 ran-
ts.ment variability.3. The main determinant of the EOA of trans-
catheter valves is the size of the patient’s
annulus.
4. In this high-risk population with a high pro-
portion of patients with small aortic annulus,
transcatheter bioprostheses provided an excel-
lent hemodynamic performance, and the inci-
dence of severe prosthesis–patient mismatch
was low.
Method for the measurement of the EOA of transcath-
eter valves. There have been some discrepancies
among previous studies with regard to the method
used for the measurement of the EOA in native
aortic valve stenosis. The method described origi-
nally (12,13) and used in numerous articles and
textbooks (14,15) was Method #1, where the
LVOT diameter is measured at the base of the
aortic valve cusps and the pulsed-wave Doppler
sample volume is positioned in the center of the
LVOT 0.5 to 1.0 cm below the aortic annulus.
However, in the most recent recommendations of
the American Society of Echocardiography/
European Association of Echocardiography pub-
lished in 2009 for the echocardiographic assessment
of native valve stenosis (16), the authors recom-
mended measuring both the LVOT diameter and
the LVOT velocity at 0.5 to 1.0 cm below the aortic
valve annulus. In the 2009 American Society of
Echocardiography guidelines for the Doppler-
echocardiographic assessment of prosthetic valve
function, it is recommended to measure the LVOT
diameter just beneath the prosthesis sewing ring (2).
For the measurement of the EOA of TAVI valves,
some investigators (4) have applied Method #1 (i.e.,
LVOT measured within the stent at the base of
bioprosthetic valve leaflets), whereas other investiga-
tors (5,6) have applied Method #2 (i.e., LVOT mea-
sured just proximal to the stent). In addition, most of
the investigators have not described the method used to
determine the EOA of transcatheter valves (17–20).
The results of the present study suggest that
Method #2 provides a more accurate and reliable
estimate of valve EOA following TAVI. The
higher intraobserver and interobserver variability of
Method #1 compared with Method #2 is most
likely related to the fact that precise identification of
the base of the bioprosthetic cusps is often difficult
because of the reverberations and acoustic shadow-
ing created by the prosthesis stent and by the
calcification of the native aortic valve and annulus.
Conversely with Method #2, the proximal (i.e.,
ventricular) border of the stent provides more pre-M
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1059tion the measurements of LVOT diameter and
velocity at serial Doppler echocardiographic exams
during follow-up. As expected, the LVOT diameter
measured with Method #2 was larger than the
LVOT diameter measured with Method #1 because
the former includes the stent, whereas the later
excludes it (Fig. 1). Nonetheless, the LVOT diam-
eter measured immediately proximal to the stent
(Method #2) is likely more appropriate for the
estimation of stroke volume and EOA because, in
the case of transcatheter balloon-expandable valves,
it is measured at about the same location of velocity
sampling. In balloon-expandable valves, the apical
ventricular border of the stent is indeed close (5
mm) to the base of the bioprosthetic valve leaflets,
and the flow is thus often accelerated within the
proximal portion of the stent. The pulsed-wave
Doppler sample should thus be positioned just
proximal to the prosthesis stent to avoid this in-
stent subvalvular flow acceleration.
The LVOT diameter and thus the EOA calcu-
lated by Method #1 decreased during follow-up,
whereas those measured by Method #2 remained
stable. This finding may be, at least in part, related
to the higher variability of LVOTd1 measurement.
It is also possible that, following TAVI, there is
some recoil phenomenon at the level of the native
aortic annulus (approximate location of LVOTd1
measurement), where the radial forces applied on
the stent are likely more important. This phenom-
enon would not occur, or would occur to a lesser
extent, beneath the native annulus (location of
LVOTd2 measurement). Fibrocalcific remodeling
may also develop around the prosthesis stent after
TAVI, thereby increasing the reverberations and
acoustic shadowing over the region of bioprosthetic
valve cusps at late follow-up. This phenomenon
may have contributed to more pronounced under-
estimation of LVOT diameter at 1-year follow-up.
Determinants of transcatheter valve EOA. In patients
with surgical prostheses, there is a relatively good
correlation between the label valve size and the
EOA for a given model of prosthesis (1). In the
present study, there was only a weak correlation
between TAVI prosthesis size and valve EOA, and
the sole independent determinant of the EOA was
the patient’s annulus diameter. As opposed to
surgical prostheses, the TAVI prostheses are de-
ployed within the aortic annulus, and the same size
of prosthesis is used for a relatively wide range of
annulus size: e.g., the 23-mm Edwards-SAPIEN
valve is used for annulus sizes ranging from 17 to 21
mm, and the 26-mm valve is used for annulus sizeof 22 to 25 mm. The main factor limiting the full
expansion of the valve, and thus the EOA, is the size
of the patient’s aortic annulus. As a matter of fact, the
average EOA of the 23-mm valve was 1.37 0.23
cm2 for annulus size19 mm versus 1.57 0.34 cm2
for 21-mm annulus size, whereas the average EOA of
the 26-mm valve was 1.61 0.17 cm2 for 22-mm
nnulus size versus 1.90 0.17 cm2 for annulus size
23 mm (Table 4).
Nonetheless, even after accounting for the prosthe-
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Figure 4. Correlations Between Mean Pressure Gradient and Ind
This ﬁgure shows the correlation between mean transprosthetic gra
effective oriﬁce area (EOA) in the subset of patients (n  84) with a
index 35 ml/m2. In A, EOA was measured by Method #1, and in B
Method #2..8 2.22.0
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1060rate, a large part of the EOA variance remains
unexplained, thus suggesting that other factors may be
involved. The amount and distribution of calcium
within the valve and annulus as well as the position of
the prosthesis relative to the aortic annulus are among
the other factors that could contribute to the variance
of the EOA of TAVI valves. In this regard, Jilaihawi
(4) reported that the valve positioning may influence
he valve EOA, and thus the occurrence of PPM, after
AVI with the CoreValve prosthesis (Medtronic,
inneapolis, Minnesota).
ic Parameters of the Edwards-SAPIEN Bioprosthesis in the
 84) With Stoke Volume Index >35 ml/m2
n
Valve EOA*
(cm2)
Mean Gradient
(mm Hg)
Doppler Velocity
Index
)
9 1.37 0.23 12 4 0.41 0.09
10 1.46 0.33 11 3 0.41 0.08
14 1.48 0.29 11 3 0.41 0.08
15 1.57 0.34 12 6 0.45 0.14
12 1.61 0.17 10 3 0.38 0.07
16 1.82 0.27 10 4 0.43 0.06
8 1.90 0.17 10 4 0.41 0.05
48 1.51 0.30 11 4 0.43 0.10
36 1.74 0.26 11 4 0.41 0.07
he EOA was measured by Method #2.
rea; TEE  transesophageal echocardiography.
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Figure 5. Incidence of Severe PPM According to Aortic Annulus
This ﬁgure shows the incidence of severe prosthesis–patient misma
esophageal echocardiography (TEE) at the time of the procedure. T
cohort for each annulus size category. The blue bars (Method #1) a
each annulus size category who have severe PPM.Hemodynamic performance of TAVI valves and incidence
of prosthesis–patient mismatch. The results of this
study suggest that the transcatheter prosthetic
valves have an excellent hemodynamic performance
in terms of EOA and gradients. Because TAVI is
performed in a selected group of patients who are
considered to be inoperable or at high risk for AVR,
the proportion of patients with a small aortic
annulus is very high in this series and a much larger
proportion than what is generally reported in sur-
gical series (21–23). Despite this unfavorable ana-
tomic profile, the transcatheter valves provided an
excellent hemodynamic performance and were
thereby associated with a low incidence of severe
PPM. There are currently no published data re-
garding the impact of PPM on clinical outcomes
following TAVI. However, several studies suggest
that PPM, and especially severe PPM, may have a
detrimental impact on outcomes after surgical valve
replacement, particularly in patients with depressed
systolic function or severe LV hypertrophy (1).
In a previous case-match study including 50 pa-
tients with TAVI, we reported that the EOAs and
gradients are better in transcatheter valves than in
surgical stented or stentless bioprostheses and that,
accordingly, the incidence of severe PPM is lower in
transcatheter (6%) than in surgical prostheses (stented:
28%, stentless: 20%) (5). Potential mechanisms that
could explain the superior hemodynamic performance
of transcatheter valves include the lower profile of the
meter (TEE), mm
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e
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Siz
tch
he y
nd
[J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 1 0 , 2 0 1 1
O C T O B E R 2 0 1 1 : 1 0 5 3 – 6 2
Clavel et al.
Doppler Echo Measurement of Valve Area in TAVI
1061stent compared with that of surgical prostheses, the
slight expansion of the aortic annulus during TAVI,
and the funnel shape of the valve inflow that may
contribute to minimize flow contraction.
The incidences of moderate (20%) and severe (9%)
PPM reported in the present study with the Edwards-
SAPIEN valve are similar to what has been reported
by Jilaihawi et al. (4) (moderate 32%, severe 2%) (4)
and Tzikas et al. (6) (moderate 23%, severe 16%) for
the CoreValve prosthesis. However, the results of
these studies are difficult to compare given that, as a
result of the differences in sizing between these 2 valve
models, the average patient’s annulus diameter was
smaller in the present series with Edwards-SAPIEN
(21 2 mm) than in the previous series with Core-
Valve (Jilaihawi et al. [4]: 23 2 mm; Tzikas et al.
6]: 22 2 mm). Further studies with case-match or
randomized design are necessary to compare the
hemodynamic and clinical performance of these 2
models of transcatheter prostheses. In the series of
patients who underwent surgical AVR (1,21–23), the
incidence of severe PPM in the subset of patients with
a small aortic annulus (21 mm) was between 20%
and 80%, whereas in the present series with TAVI, it
was 14%. In light of these findings, TAVI appears an
interesting alternative to surgical AVR for patients
with a small aortic annulus.
Study limitations. An important proportion of patients
undergoing TAVI have prosthetic valve regurgitation.
Accordingly, in the present study, 19% of patients had
mild or moderate valve regurgitation. However, the
presence of valve regurgitation does not affect the mea-
surement of EOA of aortic prosthetic valves.
In the present series, we used the aortic annulus
size measured by TEE to select valve size, and this
parameter was found to be the most important
independent determinant of EOA. However, TEE
may underestimate the size of aortic annulus be-
cause the latter is often oval, and TEE generally
measures the smaller diameter. Some investigators
have thus suggested that multislice computed to-
mography may be superior to TEE for accurate
measurement of aortic annulus size (24).
In the present study, we present the 1-year
Doppler echocardiographic follow-up. A recent
study from Gurvitch et al. (17) that included 70reported a slight deterioration in EOAs and gradi-
ents of Edwards-SAPIEN prostheses. Our study is
monocentric and included a relatively small number
of patients. Further studies with a larger number of
patients, longer follow-up, and analysis of echocar-
diographic images in a core laboratory are thus
needed to establish the normal reference values of
the valve hemodynamic parameters of transcatheter
valves and to determine whether their hemody-
namic performance is maintained in the long term.
However, in such studies, it is recommended to use
Method #2 to measure EOA because the utilization
of Method #1 could lead the investigators to falsely
conclude that there is a deterioration of hemody-
namic performance, as illustrated in Table 1. Fur-
thermore, it is preferable to use a multiparametric
approach integrating the measures of valve EOA,
transvalvular gradients, and Doppler velocity index
and their serial changes over time to adequately
identify and quantify prosthetic valve dysfunction
(1,2). Finally, the results of this study cannot be
extended to other models of TAVI valves, such as
the CoreValve, for example.
C O N C L U S I O N S
When estimating the EOA of transcatheter balloon-
expandable valves by Doppler echocardiography, it is
preferable to use the LVOT diameter and velocity
measured immediately proximal to the prosthesis
stent. The main determinant of the EOA of trans-
catheter valves is the patient’s annulus size since this is
the main factor determining the size of the biopros-
thesis as well as the magnitude of its expansion during
implantation. This study also shows that TAVI pro-
vides an excellent hemodynamic performance and
that, accordingly, the incidence of severe PPM is low,
even in patients with a small aortic annulus.
Acknowledgments
The authors thank Jacinthe Aube, Jocelyn Beauche-
min, and Nathalie Boudreault for the data collection.
Reprint request and correspondence: Dr. Philippe Pibarot,
Institut Universitaire de Cardiologie et de Pneumologie
de Québec, 2725 Chemin Sainte-Foy, Québec, Québec
G1V-4G5, Canada. E-mail: philippe.pibarot@med.patients of whom 37 reached 3-year follow-up, ulaval.ca.
11
1
1
1
1
1
1
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 1 0 , 2 0 1 1
O C T O B E R 2 0 1 1 : 1 0 5 3 – 6 2
Clavel et al.
Doppler Echo Measurement of Valve Area in TAVI
1062R E F E R E N C E S
1. Pibarot P, Dumesnil JG. Prosthetic
heart valves: selection of the optimal
prosthesis and long-term manage-
ment. Circulation 2009;119:1034–48.
2. Zoghbi WA, Chambers JB, Dumesnil
JG, et al. Recommendations for eval-
uation of prosthetic valves with echo-
cardiography and doppler ultrasound:
a report from the American Society of
Echocardiography’s Guidelines and
Standards Committee and the Task
Force on Prosthetic Valves. J Am Soc
Echocardiogr 2009;22:975–1014.
3. Moss RR, Ivens E, Pasupati S, et al.
Role of echocardiography in percuta-
neous aortic valve implantation. J Am
Coll Cardiol Img 2008;1:15–24.
4. Jilaihawi H, Chin D, Spyt T, et al.
Prosthesis-patient mismatch after trans-
catheter aortic valve implantation with
the Medtronic-CoreValve bioprosthe-
sis. Eur Heart J 2010;31:857–64.
5. Clavel MA, Webb JG, Pibarot P, et
al. Comparison of the hemodynamic
performance of percutaneous and sur-
gical bioprostheses for the treatment
of severe aortic stenosis. J Am Coll
Cardiol 2009;53:1883–91.
6. Tzikas A, Piazza N, Geleijnse ML, et
al. Prosthesis-patient mismatch after
transcatheter aortic valve implantation
with the medtronic CoreValve system
in patients with aortic stenosis. Am J
Cardiol 2010;106:255–60.
7. Garcia D, Pibarot P, Dumesnil JG,
Sakr F, Durand LG. Assessment of
aortic valve stenosis severity: a new
index based on the energy loss con-
cept. Circulation 2000;101:765–71.
8. Burwash IG. Low-flow, low-gradient
aortic stenosis: from evaluation to
treatment. Curr Opin Cardiol 2007;
22:84–91.
9. Hachicha Z, Dumesnil JG, Bogaty
P, Pibarot P. Paradoxical low flow,
low gradient severe aortic stenosisdespite preserved ejection fraction is
associated with higher afterload and
reduced survival. Circulation 2007;
115:2856 – 64.
0. Minners J, Allgeier M, Gohlke-
Baerwolf C, Kienzle RP, Neumann
FJ, Jander N. Inconsistent grading of
aortic valve stenosis by current guide-
lines: haemodynamic studies in pa-
tients with apparently normal left ven-
tricular function. Heart 2010;96:
1463–8.
1. Bland JM, Altman DG. Statistical
methods for assessing agreement be-
tween two methods of clinical mea-
surement. Lancet 1986;1:307–10.
2. Skjaerpe T, Hegrenaes L, Hatle L.
Noninvasive estimation of valve area
in patients with aortic stenosis by
Doppler ultrasound and two-
dimensional echocardiography. Circu-
lation 1985;72:810–8.
3. Otto CM, Pearlman AS, Comess KA,
Reamer RP, Janko CL, Huntsman
LL. Determination of the stenotic
aortic valve area in adults using Dopp-
ler echocardiography. J Am Coll Car-
diol 1986;7:509–17.
4. Bednarz JE, Krauss D, Lang RM. An
echocardiographic approach to the as-
sessment of aortic stenosis. J Am Soc
Echocardiogr 1996;9:286–94.
5. Oh JK, Seward JB, Tajik AJ. Valvular
heart disease. In: Weinberg RW,
Simmons LA, Madrigal R, editors.
The Echo Manual. Philadelphia, PA:
Lippincott-Raven, 1999:103–32.
6. Baumgartner H, Hung J, Bermejo J,
et al. Echocardiographic assessment of
valve stenosis: EAE/ASE recommen-
dations for clinical practice. J Am Soc
Echocardiogr 2009;22:1–23.
7. Gurvitch R, Wood DA, Tay EL, et al.
Transcatheter aortic valve implanta-
tion: durability of clinical and hemo-
dynamic outcomes beyond 3 years in a
large patient cohort. Circulation 2010;
122:1319–27.18. Webb JG, Pasupati S, Humphries K,
et al. Percutaneous transarterial aortic
valve replacement in selected high-
risk patients with aortic stenosis. Cir-
culation 2007;116:755–63.
19. Himbert D, Descoutures F, Al Attar
N, et al. Results of transfemoral or
transapical aortic valve implantation
following a uniform assessment in
high-risk patients with aortic stenosis.
J Am Coll Cardiol 2009;54:303–11.
20. Leon MB, Smith CR, Mack M, et al.
Transcatheter aortic-valve implanta-
tion for aortic stenosis in patients who
cannot undergo surgery. N Engl
J Med 2010;363:1597–607.
21. Mohty D, Dumesnil JG, Echahidi N,
et al. Impact of prosthesis-patient
mismatch on long-term survival after
aortic valve replacement: influence of
age, obesity, and left ventricular dys-
function. J Am Coll Cardiol 2009;53:
39–47.
22. Kohsaka S, Mohan S, Virani S, et al.
Prosthesis-patient mismatch affects
long-term survival after mechanical
valve replacement. J Thorac Cardio-
vasc Surg 2008;135:1076–80.
23. Walther T, Rastan A, Falk V, et al.
Patient prosthesis mismatch affects
short- and long-term outcomes after
aortic valve replacement. Eur J Car-
diothorac Surg 2006;30:15–9.
24. Ng AC, Delgado V, van der KF, et al.
Comparison of aortic root dimensions
and geometries before and after trans-
catheter aortic valve implantation by
2- and 3-dimensional transesophageal
echocardiography and multislice com-
puted tomography. Circ Cardiovasc
Imaging 2010;3:94–102.
Key Words: aortic stenosis y
echocardiography y prosthesis y
transcatheter y valves.
